Eylea (aflibercept) is a prescription injection that treats certain eye diseases. Eylea’s cost may depend on your treatment plan, whether you have health insurance, and which doctor’s office ...

Despite Eylea reaching the market first, Roche has eroded a stake of Bayer’s market share with its bispecific antibody Vabysmo. Similar to Eylea, Vabysmo is approved for a range of retinal ...

Regeneron Pharmaceuticals, Inc. REGN announced disappointing top-line data from an ongoing phase II CAPELLA study, evaluating Eylea (aflibercept) in combination with rinucumab (an anti-PDGFR-beta ...

On a standalone basis, Eylea sales were $1.19 billion in the United States in the fourth quarter of 2024. Eylead HD’s net product sales were $305 million in the fourth quarter of 2024 in the ...

Moreover, Eylea was well tolerated during the study. Eylea is already submitted in the U.S. for the BRVO indication. A final decision from the FDA on the approval of Eylea is expected by Oct 23, 2014.

Regeneron Pharmaceuticals Inc's first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heated up, dragging the company's shares more than 5% ...

Kodiak Sciences Inc's eye drug failed to match Regeneron Pharmaceuticals' Eylea in improving the vision of patients in a study, sending its shares tumbling nearly 80% on Wednesday.

Regeneron announced phase 3 development of a combination of Eylea and the angiopoietin2 antibody nesvacumab is not warranted after two phase 2 trials failed to show sufficient differentiation ...

Eylea generated $5.72 billion in total U.S. sales last year, which represented 44% of Regeneron’s overall revenue of $13.12 billion. Related Unlike Regeneron, Bayer doesn't feel as much of a ...

Regeneron Pharmaceuticals Inc. said an extensive investigation into a rare and frightening side effect seen in clusters of patients getting its best-selling drug Eylea has been tied to syringes ...

Eylea will run $1,850 per dose, Bloomberg reports, compared with $2,000 for Lucentis, and $16,000 for a full year, compared with $24,000 for the Roche drug.